Acute and Long-term Adverse Events Associated With Checkpoint Blockade

被引:9
作者
Davies, Marianne [1 ,2 ]
机构
[1] Yale Univ, Sch Nursing, POB 27399, West Haven, CT 06516 USA
[2] Yale Comprehens Canc Ctr, New Haven, CT USA
关键词
Immune checkpoint inhibitors; ICPI; Immune mediated adverse events; Immune related adverse events; IrAE; DEATH; 1; ADVANCED MELANOMA; IMMUNE; INHIBITORS; CANCER; ANTI-PD-1; MANAGEMENT; ENDOCRINE; IPILIMUMAB; THERAPY;
D O I
10.1016/j.soncn.2019.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To provide an overview of the spectrum of immune-related adverse events associated with immune checkpoint therapy, including presentation, evaluation, management, and nursing considerations. Data Sources: Peer-reviewed articles, published literature, national guidelines, Internet. Conclusion: Immune checkpoint inhibitor therapies are have become a therapeutic treatment options for many cancers. These therapies promote activity of a patient's adaptive immune system to eradicate cancer. The agents are associated with a unique side-effect profile called Immune-related adverse events. Most of these are low severity. However, if they become more severe, they can be life-threatening or result in permanent organ dysfunction. The key to optimizing therapies is collaborative monitoring, evaluation, documentation, management, communication. Implications for Nursing Practice: Oncology nurses are the front line of patient care. Nurses must have a thorough understanding of the mechanism of action, potential immune-related adverse events, clinical implications, and management strategies. They are responsible for educating patients about immune checkpoint therapies and the potential side effects that may develop, triage management strategies, and coordination of care. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页数:13
相关论文
共 85 条
  • [1] Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
    Abdel-Rahman, Omar
    Oweira, Hani
    Petrausch, Ulf
    Helbling, Daniel
    Schmidt, Jan
    Mannhart, Meinrad
    Mehrabi, Arianeb
    Schoeb, Othmar
    Giryes, Anwar
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 387 - 394
  • [2] Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
    Abdel-Wahab, Noha
    Shah, Mohsin
    Lopez-Olivo, Maria A.
    Suarez-Almazor, Maria E.
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 168 (02) : 121 - +
  • [3] Abdul-Wahab N, 2017, J IMMUNOTHER CANC S2, V5, pP444
  • [4] Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis
    Abu-Sbeih, Hamzah
    Ali, Faisal S.
    Wang, Xuemei
    Mallepally, Niharika
    Chen, Ellie
    Altan, Mehmet
    Bresalier, Robert S.
    Charabaty, Aline
    Dadu, Ramona
    Jazaeri, Amir
    Lashner, Bret
    Wang, Yinghong
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [5] Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
    Abu-Sbeih, Hamzah
    Tang, Tenglong
    Lu, Yang
    Thirumurthi, Selvi
    Altan, Mehmet
    Jazaeri, Amir A.
    Dadu, Ramona
    Coronel, Emmanuel
    Wang, Yinghong
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
    Arbour, Kathryn C.
    Mezquita, Laura
    Long, Niamh
    Rizvi, Hira
    Auclin, Edouard
    Ni, Andy
    Martinez-Bernal, Gala
    Ferrara, Roberto
    Lai, W. Victoria
    Hendriks, Lizza E. L.
    Sabari, Joshua K.
    Caramella, Caroline
    Plodkowski, Andrew J.
    Halpenny, Darragh
    Chaft, Jamie E.
    Planchard, David
    Riely, Gregory J.
    Besse, Benjamin
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2872 - +
  • [7] A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors
    Arnaud-Coffin, Patrick
    Maillet, Denis
    Gan, Hui K.
    Stelmes, Jean-Jacques
    You, Benoit
    Dalle, Stephane
    Peron, Julien
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (03) : 639 - 648
  • [8] Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
    Astaras, Christophoros
    de Micheli, Rita
    Moura, Bianca
    Hundsberger, Thomas
    Hottinger, Andreas F.
    [J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2018, 18 (01)
  • [9] Prevention and Treatment of Cancer-Related Infections
    Baden, Lindsey Robert
    Bensinger, William
    Angarone, Michael
    Casper, Corey
    Dubberke, Erik R.
    Freifeld, Alison G.
    Garzon, Ramiro
    Greene, John N.
    Greer, John P.
    Ito, James I.
    Karp, Judith E.
    Kaul, Daniel R.
    King, Earl
    Mackler, Emily
    Marr, Kieren A.
    Montoya, Jose G.
    Morris-Engemann, Ashley
    Pappas, Peter G.
    Rolston, Ken
    Segal, Brahm
    Seo, Susan K.
    Swaminathan, Sankar
    Naganuma, Maoko
    Shead, Dorothy A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (11): : 1412 - 1445
  • [10] Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
    Bergqvist, Viktoria
    Hertervig, Erik
    Gedeon, Peter
    Kopljar, Marija
    Griph, Hakan
    Kinhult, Sara
    Carneiro, Ana
    Marsal, Jan
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (05) : 581 - 592